Literature DB >> 16215351

Ovarian hyperstimulation syndrome.

Marie M Budev1, Alejandro C Arroliga, Tommaso Falcone.   

Abstract

OBJECTIVE: Ovarian hyperstimulation syndrome (OHSS) is a rare iatrogenic complication of ovarian stimulation usually occurring during the luteal phase or during the early part of pregnancy. OHSS is a potential complication of ovarian induction by almost every agent used for ovarian stimulation. Today, due to aggressive treatment protocols including the development of in vitro fertilization and cryopreservation with the goal of obtaining sufficient numbers of oocytes and embryos, an increased risk of developing OHSS is present. OHSS is now becoming increasingly more recognized due to the higher number of women undergoing assisted reproductive techniques.
DESIGN: Review of the literature regarding ovarian hyperstimulation syndrome.
METHODS: A review of the epidemiology, pathophysiology, risk factors, classification, clinical features, and treatment and prevention of OHSS.
CONCLUSION: OHSS can be thought of as the loss of control over the hyperstimulation of the ovaries. Although the prevalence of the severe form of OHSS is small, it is important to remember that OHSS is usually an iatrogenic complication of a nonvital treatment that has the potential for a fatal outcome. Therefore, critical care physicians play an integral part in the care of these patients and therefore should be familiar with and recognize the various clinical manifestations and potential outcomes of this entity.

Entities:  

Mesh:

Year:  2005        PMID: 16215351     DOI: 10.1097/01.ccm.0000182795.31757.ce

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  18 in total

1.  Torsion of a hyperstimulated ovary during pregnancy: a potentially difficult diagnosis.

Authors:  Daniel Cornfeld; Leslie Scoutt
Journal:  Emerg Radiol       Date:  2007-04-04

2.  Risk Factors and Methods for Predicting Ovarian Hyperstimulation Syndrome (OHSS) in the in vitro Fertilization.

Authors:  S P Pakhomov; V S Orlova; I N Verzilina; N V Sukhih; A V Nagorniy; A V Matrosova
Journal:  Arch Razi Inst       Date:  2021-11-30

3.  Severe ovarian hyperstimulation syndrome leading to ICU admission.

Authors:  R K Singh; Sanjay Singhal; Afzal Azim; A K Baronia
Journal:  Saudi J Anaesth       Date:  2010-01

4.  Egg sharing in return for subsidized fertility treatment--ethical challenges and pitfalls.

Authors:  Boon Chin Heng
Journal:  J Assist Reprod Genet       Date:  2008-04       Impact factor: 3.412

5.  Acute ischaemic stroke in pregnancy: a severe complication of ovarian hyperstimulation syndrome.

Authors:  Andrea Bartkova; Daniel Sanak; Jiri Dostal; Roman Herzig; Pavel Otruba; Ivanka Vlachova; Petr Hlustik; David Horak; Petr Kanovsky
Journal:  Neurol Sci       Date:  2008-10-15       Impact factor: 3.307

6.  Legal and ethical issues in the international transaction of donor sperm and eggs.

Authors:  Boon Chin Heng
Journal:  J Assist Reprod Genet       Date:  2007-02-16       Impact factor: 3.412

Review 7.  Liver X Receptors and female reproduction: when cholesterol meets fertility!

Authors:  J M A Lobaccaro; D Gallot; S Lumbroso; K Mouzat
Journal:  J Endocrinol Invest       Date:  2012-11-27       Impact factor: 4.256

8.  An update on the prevention of ovarian hyperstimulation syndrome.

Authors:  Omar El Tokhy; Julia Kopeika; Tarek El-Toukhy
Journal:  Womens Health (Lond)       Date:  2016-08-19

9.  Cellular reprogramming for the creation of patient-specific embryonic stem cells.

Authors:  Jose B Cibelli; Arif M Kocabas; Zeki Beyhan; Pablo J Ross
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

10.  Absence of nuclear receptors for oxysterols liver X receptor induces ovarian hyperstimulation syndrome in mice.

Authors:  Kevin Mouzat; Fanny Volat; Silvère Baron; Georges Alves; Aurélien J C Pommier; David H Volle; Geoffroy Marceau; Angélique DeHaze; Pierre Déchelotte; Raj Duggavathi; Françoise Caira; Jean-Marc A Lobaccaro
Journal:  Endocrinology       Date:  2009-03-26       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.